Measuring and Valuing Outcomes
We conduct applied and methodological research to identify and understand the outcomes that matter to patients, carers, and/or society, the value they assign to those outcomes, and how best to incorporate these outcomes and values in decision-making.
OHE has a longstanding reputation for leading innovative and theoretically sound research on the measurement and valuation of health outcomes. Our research is global in scope, is published in top peer-reviewed academic journals, and disseminated widely at international conferences.
Our expertise includes:
- Quantitative patient preference studies using discrete choice experiments (DCEs) and best-worst scaling (BWS)
- Qualitative research to explore patient experiences and carer burden via interviews, focus groups, and online bulletin boards
- Societal preference studies exploring public priorities for treatment funding decisions and broader health policies using person trade-off (PTO) and constant-sum paired comparisons (CSPC)
- Patient and carer utility (vignette) studies to inform health economic models using time trade-off (TTO)
- Generating rigorous real-world evidence (RWE) to complement trial data
- Development and validation of EQ-5D bolt-on items
- Patient-reported outcome (PRO) strategy and psychometric analyses
- Mapping between condition-specific and generic measures
- Production of country-specific PRO value sets, including for younger populations
- Methodological research on valuation methods, including novel methods such as the online personal utility functions (OPUF) tool
Key objectives for this research theme:
- To facilitate the measurement and valuation of outcomes for health technology assessment (HTA)
- To understand the preferences of patients, their carers, and clinicians to inform health care decision making
- To understand the preferences of society to inform health policy decisions
Our latest content on this theme
Patient preferences for treatment in relapsed/refractory acute leukemia
When acute leukemia relapses, treatment decisions can be complex. Patients may face trade-offs between survival benefits, side effects and how treatment is delivered. This study asked people with acute leukemia across five countries what matters most to them when making these choices.
Understanding the preferences of people with acute leukemia for different health outcomes
When we want to understand or measure someone’s “health-related quality-of-life”, we typically ask them to describe the problems they have with different aspects of their health. In this study, we wanted to understand which aspects, or “dimensions”, of health-related quality-of-life are most important to the general public and to persons with acute leukemia.
OHE submission to the UK Parliamentary Inquiry on an Ageing Society
OHE’s written submission to parliament focused on raising population health in older age and increasing access to fertility treatments as two possible avenues to address the challenges of demographic change.
GLP-1 Receptor Agonists: Shifting Obesity Management
The glucagon-like peptide-1 (GLP-1) receptor agonist market is experiencing rapid growth, with more than 150 drug candidates currently in development as reported by Research & Markets,…